NEW YORK, NY / ACCESSWIRE / November 14, 2020 / Pomerantz LLP is investigating claims on behalf of investors of NextCure ("NextCure" or the "Company") (NASDAQ:NXTC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether NextCure and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On January 13, 2020, NextCure disclosed in a U.S. Securities and Exchange Commission filing that Eli Lilly and Company had ended its 2018 research and development collaboration agreement with NextCure.
On this news, NextCure's stock price fell $4.70 per share, or 8.29%, to close at $52.00 per share on January 13, 2020.
Then, on July 13, 2020, NextCure issued a press release announcing that the Company no longer planned to "advance the non-small cell lung cancer (NSCLC) and ovarian cancer cohorts in the stage 2 portion of the Simon 2-stage trial" for its NC318 immunomedicine product, citing "clinical response data" and "current enrollment criteria." NextCure concurrently announced the resignation of Kevin N. Heller from his role as the Company's Chief Medical Officer.
On this news, NextCure's stock price fell $9.73 per share, or more than 54%, to close at $8.15 per share on July 13, 2020.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
SOURCE: Pomerantz LLP